cbdMD, Inc. (YCBD) P/E Ratio History
Deep ValueTrading at -0.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2020
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, cbdMD, Inc. (YCBD) trades at a price-to-earnings ratio of -0.6x, with a stock price of $0.69 and trailing twelve-month earnings per share of $-0.25.
The current P/E is 100% below its 5-year average of 555.6x. Over the past five years, YCBD's P/E has ranged from a low of 15.8x to a high of 2114.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, YCBD trades at a 103% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, YCBD trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our YCBD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
YCBD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
YCBD P/E vs Peers
Cannabis and cannabinoid product companies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 26.9Lowest | 1.17Best | -25% | |
| $7B | 65.8 | - | -4%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
YCBD Historical P/E Data (2018–2020)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2020 Q4 | Sep 30 2020 | $720.00 | $17.77 | 40.5x | -93% |
| FY2020 Q3 | - | $687.60 | $43.51 | 15.8x | -97% |
| FY2020 Q2 | - | $334.80 | $6.45 | 51.9x | -91% |
| FY2018 Q3 | Jun 30 2018 | $1332.00 | $0.63 | 2114.3x | +281% |
Average P/E for displayed period: 555.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
YCBD — Frequently Asked Questions
Quick answers to the most common questions about buying YCBD stock.
What is YCBD's P/E ratio?
cbdMD, Inc. (YCBD) trailing twelve-month P/E ratio is -0.6x, based on TTM diluted EPS of $-0.25. The 5-year average P/E is 555.6x and the historical range spans 15.8x to 2114.3x.
Is YCBD stock overvalued or undervalued?
YCBD trades at -0.6x P/E, below its 5-year average of 555.6x. At the 0th percentile of its historical range (15.8x–2114.3x), the stock is priced at a discount to its own history.
Is YCBD stock expensive?
No, YCBD is not expensive on a historical basis. The current P/E of -0.6x is below the 5-year average of 555.6x and sits at the 0th percentile of its valuation range.
What is YCBD's historical P/E range?
Over the past 5 years, YCBD's P/E ratio has ranged from 15.8x to 2114.3x, with a median of 51.9x and an average of 555.6x. The current P/E of -0.6x places the stock at the 0th percentile of this range. Full historical data spans 2018–2020.
How does YCBD's P/E compare to the S&P 500?
YCBD trades at -0.6x P/E versus the S&P 500 median of 24.3x. The 102% discount to the market suggests lower growth expectations or perceived higher risk.
How does YCBD's valuation compare to Healthcare peers?
cbdMD, Inc. P/E of -0.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is YCBD's PEG ratio?
YCBD PEG ratio is N/A, based on a P/E of -0.6x and EPS growth of 39.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is YCBD's earnings yield?
YCBD earnings yield is N/A, the inverse of its -0.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.